Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Enorama Pharma's nicotine chewing gum is an over-the-counter (OTC) nicotine replacement therapy (NRT) designed to aid in smoking cessation and the treatment of nicotine dependence. Developed using the proprietary ChewMed® compressed gum technology platform, the product delivers nicotine via buccal absorption to reduce withdrawal symptoms and cravings. It is available in 2 mg and 4 mg strengths and has been demonstrated to be bioequivalent to Nicorette®. The product is currently approved and marketed in several European countries, including Sweden, France, Spain, and Germany, providing a tobacco-free source of nicotine to help manage addiction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Enorama Nicotine Chewing Gum.